BioSpace News Archive

Olink Proteomics World 2025 is a digital event showcasing the latest breakthroughs in proteomics, precision health, population-scale studies, and disease research. Learn how proteomics is reshaping biomedical research and advancing healthcare. The programme features three main tracks. Multiomics & Precision Health highlights how proteomics complements GWAS, leverages UK Biobank data, and standardises workflows. Population Proteomics explores diversity in cohort studies and shows how combining mass spectrometry and affinity-based platforms expands proteome coverage. Disease-Focused Applications provide practical insights into neurology, oncology, and infectious diseases, with a strong emphasis on translational impact. What to expect: expert-led talks, tutorials, and panel discussions; real-world use cases of Olink® solutions; live interaction with researchers and Olink experts; plus virtual booths and poster presentations. All sessions are free to attend and available live or on demand, with event times tailored for both EMEA+APAC and AMR audiences.

Research teams around the world are focused on the power of mRNA. As mRNA continues to enter and be adopted by the global healthcare community, the need to quickly validate and scale these therapeutics becomes more critical. This discussion focuses on how sequencing-based insights can power AI-driven design and data-driven validation, helping to develop safe and effective drugs for treating and preventing disease.

Looking for a biopharma job in San Francisco or South San Francisco? Check out the BioSpace list of eight companies hiring life sciences professionals like you.

Novo Nordisk has brought on other cardiometabolic collaborators this year, including United Laboratories International and Deep Apple Therapeutics.

Exelixis is looking at the possibility of relocating some of the eliminated Pennsylvania roles to its headquarters in Alameda, California, according to a company spokesperson.

The CDC director—the first to be confirmed by the Senate under new legislation—has been ousted after less than a month following internal unrest regarding new, more restrictive approvals for updated COVID-19 vaccines, according to multiple sources.

Sometimes, job interviews stand out for all the wrong reasons, including odd settings, off-topic topics and questionable decorum. BioSpace collected several stories that highlight biopharma professionals’ strangest experiences as they pursued employment.

In another blow to Prothena’s neurodegenerative disease portfolio, anti-amyloid candidate PRX012 has run into the same problem that larger peers Biogen and Eli Lilly have battled: high rates of swelling in the brain.

The American Academy of Pediatrics called the decision to limit children’s access to COVID-19 vaccines “deeply troubling.”